NCT00175045View on ClinicalTrials.gov

Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

October 31, 2003

Study Completion Date

October 31, 2003

Conditions
EsophagitisReflux
Interventions
DRUG

Lansoprazole

Lansoprazole 30 mg, intravenous injection, once daily for up to 7 days.

DRUG

Lansoprazole

Lansoprazole 30 mg, capsules, orally, once daily for up to 7 days.

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY